KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Retained Earnings (2017 - 2025)

Amneal Pharmaceuticals has reported Retained Earnings over the past 9 years, most recently at -$110.7 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$110.7 million for Q4 2025, down 69.03% from a year ago — trailing twelve months through Dec 2025 was -$110.7 million (down 69.03% YoY), and the annual figure for FY2025 was -$110.7 million, down 69.03%.
  • Retained Earnings for Q4 2025 was -$110.7 million at Amneal Pharmaceuticals, down from -$105.9 million in the prior quarter.
  • Over the last five years, Retained Earnings for AMRX hit a ceiling of $8.1 million in Q2 2023 and a floor of -$594.9 million in Q1 2025.
  • Median Retained Earnings over the past 5 years was -$108.3 million (2025), compared with a mean of -$231.7 million.
  • Peak annual rise in Retained Earnings hit 102.02% in 2023, while the deepest fall reached 118274.21% in 2023.
  • Amneal Pharmaceuticals' Retained Earnings stood at -$24.8 million in 2021, then plummeted by 1536.05% to -$406.2 million in 2022, then dropped by 20.68% to -$490.2 million in 2023, then surged by 86.64% to -$65.5 million in 2024, then tumbled by 69.03% to -$110.7 million in 2025.
  • The last three reported values for Retained Earnings were -$110.7 million (Q4 2025), -$105.9 million (Q3 2025), and -$97.4 million (Q2 2025) per Business Quant data.